IHC - FLI-1 Test, Price, Normal Range | Sprint Diagnostics Hyderabad

No, fasting is not required for the IHC - FLI-1 test.

The test is usually recommended when a patient has symptoms or imaging results that suggest Ewing's sarcoma or when a healthcare professional wants to rule out other types of tumors.

The test detects the presence of the FLI-1 protein in tissue samples. A positive result for FLI-1 protein suggests the presence of Ewing's sarcoma or a related tumor, while a negative result makes these diagnoses less likely.

The IHC - FLI-1 test is not a routine test and is only done when there is a clinical suspicion of Ewing's sarcoma or related tumors.

In normal tissues, FLI-1 protein is not typically expressed. The presence of FLI-1 protein in tissue samples is considered abnormal and may indicate Ewing's sarcoma or a related tumor.

There are no special precautions needed for the IHC - FLI-1 test. However, patients should inform their doctor about any medications or supplements they are taking as they might interfere with the test results.

Yes, some other types of cancers and normal blood vessels can also express FLI-1 protein. Therefore, a positive result must be interpreted carefully in the context of clinical findings and other diagnostic tests.

If the IHC - FLI-1 test result is abnormal, it is advisable to consult an oncologist, who specializes in cancer treatment, for further evaluation and management.

Yes, the test can be used in some cases to monitor the effectiveness of treatment by evaluating the changes in FLI-1 expression in tissue samples taken before and after therapy.

Yes, apart from Ewing's sarcoma, FLI-1 is also expressed in some lymphomas. However, it is primarily used in the diagnosis of Ewing's sarcoma and related tumors.

Treatment for Ewing's sarcoma usually includes a combination of surgery, chemotherapy, and radiation therapy. The specific treatment plan depends on various factors, including the stage of the cancer, the patient's overall health, and the location of the tumor.

The IHC - FLI-1 test itself involves minimal risk. However, since it requires a tissue sample, there may be risks associated with the biopsy procedure used to obtain the sample, such as infection or bleeding.

Yes, the level of FLI-1 protein expression can sometimes give information about the aggressiveness of the tumor and the likely response to treatment, which can be helpful in predicting the prognosis.

It's crucial to recognize the role that the IHC - FLI-1 diagnostic test plays in diagnosing Ewing's sarcoma and similar tumors. The detection of FLI-1 protein can be a significant piece of the puzzle in the diagnostic process. If you or a loved one are advised to take this test, knowing what to expect and understanding its importance can be a valuable part of managing and dealing with the diagnosis. If the test is positive, it’s important to follow through with the recommended treatment plan and maintain open communication with your doctor.